Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2021 Feb 4

PMID 33536774

Citations 3

Authors

Renata Sokolik

Milena Iwaszko

Jerzy Swierkot

Barbara Wysoczanska

Lucyna Korman

Piotr Wiland

Katarzyna Bogunia-Kubik

Affiliations

Soon will be listed here.

Abstract

Introduction: The purpose of the study was to investigate whether single-nucleotide polymorphisms (SNPs) IL-6 -174 G/C and IL-6R Asp358Ala are associated with susceptibility to psoriatic arthritis (PsA) or affect response to treatment with methotrexate (MTX).

Patients And Methods: Seventy-four patients diagnosed with PsA and qualified for MTX treatment were enrolled to the study. The control group consisted of 120 healthy individuals. Polymorphisms IL-6 -174 G/C and IL-6R Asp358Ala were genotyped using a polymerase chain reaction (PCR) amplification employing LightSNiP assays.

Results: A significant association between the IL-6 -174 CC genotype and an improved clinical outcome of MTX therapy was observed. A good response was more frequently observed among PsA patients bearing the IL-6 -174 CC genotype than patients with the GC or GG genotypes ( = 0.007). On the other hand, patients carrying the IL-6 -174 GC genotype less frequently responded to MTX treatment as compared to patients with other genotypes ( = 0.006). With respect to the IL-6R Asp358Ala SNP, there were no significant differences in genotype and allelic frequencies in relation to clinical outcome of MTX treatment. No association was found between the IL-6 -174 G/C or IL-6R Asp358Ala SNPs and PsA susceptibility.

Conclusion: Results from this study provide evidence that the IL-6 -174 G/C polymorphism might influence efficacy of MTX treatment.

Citing Articles

Systematic Review on the Role of IL-6 and IL-1β in Cardiovascular Diseases.

Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A J Cardiovasc Dev Dis. 2024; 11(7).

PMID: 39057626 PMC: 11277031. DOI: 10.3390/jcdd11070206.

No Association of Polymorphisms in the Genes Encoding Interleukin-6 and Interleukin-6 Receptor Subunit Alpha with the Risk of Keloids in Polish Patients.

Dmytrzak A, Lewandowska K, Boron A, Loniewska B, Grzesch N, Brodkiewicz A Int J Mol Sci. 2024; 25(10).

PMID: 38791322 PMC: 11121548. DOI: 10.3390/ijms25105284.

The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review.

Ortolan A, Cozzi G, Lorenzin M, Galozzi P, Doria A, Ramonda R Front Genet. 2021; 12:703911.

PMID: 34354741 PMC: 8329488. DOI: 10.3389/fgene.2021.703911.

References

Schotte H, Schmidt H, Gaubitz M, Drynda S, Kekow J, Willeke P . Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. Clin Rheumatol. 2015; 34(12):2021-8. DOI: 10.1007/s10067-015-3107-7. View

Enevold C, Baslund B, Linde L, Josephsen N, Tarp U, Lindegaard H . Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014; 24(8):401-5. DOI: 10.1097/FPC.0000000000000071. View

Zavaleta-Muniz S, Martin-Marquez B, Gonzalez-Lopez L, Gonzalez-Montoya N, Diaz-Toscano M, Ponce-Guarneros J . The -174G/C and -572G/C interleukin 6 promoter gene polymorphisms in mexican patients with rheumatoid arthritis: a case-control study. Clin Dev Immunol. 2013; 2013:959084. PMC: 3794651. DOI: 10.1155/2013/959084. View

Galicia J, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H . Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004; 5(6):513-6. DOI: 10.1038/sj.gene.6364120. View

Goupille P . Psoriatic arthritis. Joint Bone Spine. 2005; 72(6):466-70. DOI: 10.1016/j.jbspin.2005.10.006. View

Ibrahim I, McAllister K, Plant D, Symmons D, Marshall T, Barton A . Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2013; 73(4):787-8. DOI: 10.1136/annrheumdis-2013-204330. View

Lee Y, Lee H, Choi S, Ji J, Song G . The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2011; 21(1):60-7. DOI: 10.1177/0961203311422711. View

Revez J, Bain L, Chapman B, Powell J, Jansen R, Duffy D . A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk. Genes Immun. 2013; 14(7):441-6. PMC: 4233139. DOI: 10.1038/gene.2013.38. View

Sarwar N, Butterworth A, Freitag D, Gregson J, Willeit P, Gorman D . Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379(9822):1205-13. PMC: 3316940. DOI: 10.1016/S0140-6736(11)61931-4. View

10.

Ogilvie E, Fife M, Thompson S, Twine N, Tsoras M, Moroldo M . The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003; 48(11):3202-6. DOI: 10.1002/art.11300. View

11.

Nowell M, Richards P, Horiuchi S, Yamamoto N, Rose-John S, Topley N . Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003; 171(6):3202-9. DOI: 10.4049/jimmunol.171.6.3202. View

12.

Davila-Fajardo C, Marquez A, Pascual-Salcedo D, Ramos M, Garcia-Portales R, Magro C . Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2013; 24(1):1-5. DOI: 10.1097/FPC.0000000000000013. View

13.

Marinou I, Walters K, Winfield J, Bax D, Wilson A . A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis. 2009; 69(6):1191-4. DOI: 10.1136/ard.2008.100644. View

14.

Heinrich P, Castell J, Andus T . Interleukin-6 and the acute phase response. Biochem J. 1990; 265(3):621-36. PMC: 1133681. DOI: 10.1042/bj2650621. View

15.

Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O . Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 2003; 48(5):1408-13. DOI: 10.1002/art.10935. View

16.

Scheller J, Rose-John S . Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006; 195(4):173-83. DOI: 10.1007/s00430-006-0019-9. View

17.

Wielinska J, Dratwa M, Swierkot J, Korman L, Iwaszko M, Wysoczanska B . Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis. HLA. 2018; 92 Suppl 2:38-41. DOI: 10.1111/tan.13355. View

18.

Assier E, Boissier M, Dayer J . Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine. 2010; 77(6):532-6. DOI: 10.1016/j.jbspin.2010.07.007. View

19.

Dernis E, Lavie F, Salliot C, Flipo R, Saraux A, Maillefert J . Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine. 2009; 76(5):524-31. DOI: 10.1016/j.jbspin.2009.03.002. View

20.

Panoulas V, Stavropoulos-Kalinoglou A, Metsios G, Smith J, Milionis H, Douglas K . Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2008; 204(1):178-83. DOI: 10.1016/j.atherosclerosis.2008.08.036. View